SEO Support Can We Slow Parkinson's? Prasinezumab and the Race to Target Alpha-Synuclein Every approved Parkinson's medicine today treats symptoms. None has been proven to slow the disease itself. That's why the progress of prasinezumab — an antibody designed to target the misfolded prote... Medication Parkinson's Research Nov 6, 2026 Parkinson's Research
SEO Support Solengepras: A Non-Dopamine Parkinson's Pill Succeeds in Phase 3 Almost every Parkinson's medicine in use today works by boosting dopamine — replacing it (levodopa), mimicking it (dopamine agonists), or slowing its breakdown (MAO-B and COMT inhibitors). On 7 Octobe... Medication Parkinson's Research Oct 20, 2026
SEO Support Tavapadon (Juvmo) Approved: What the First D1/D5 Parkinson's Pill Means for Patients In late September 2026, the US Food and Drug Administration approved tavapadon, which AbbVie will sell under the brand name Juvmo, for adults with Parkinson's disease. It is a once-daily pill, and it ... Medication Parkinson's Research Oct 17, 2026
SEO Support Understanding Levodopa-Induced Dyskinesia: Why It Happens and How It's Managed Today Levodopa remains, more than 50 years after its introduction, the single most effective medication for Parkinson's disease motor symptoms. It's also the source of one of the disease's most frustrating ... Medication Sep 1, 2026
SEO Support GLP-1 Drugs for Parkinson's: What Trials Really Showed GLP-1 Drugs for Parkinson's: What the Exenatide and Lixisenatide Trials Really Showed Diabetes drugs making headlines as possible Parkinson's treatments has been one of the more surprising research st... Medication Parkinson's Research Jul 22, 2026 Our blog
